New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 11, 2012
07:04 EDTSOMX, PTXPernix Therapeutics acquires Somaxon for $25M
Pernix Therapeutics (PTX) and Somaxon Pharmaceuticals (SOMX) announced that they have entered into a definitive merger agreement for Pernix to acquire Somaxon in a stock-for-stock transaction with a total equity value of $25M. Under the terms of the agreement, which has been unanimously approved by the boards of directors of both companies, Somaxon stockholders will receive aggregate consideration equal to $25M in Pernix common stock. The number of shares of Pernix common stock to be issued to the stockholders of Somaxon will be based on the volume-weighted average price of Pernix's common stock over the 30 day period ending on the day immediately prior to the closing of the proposed merger, subject to limitations on the maximum and minimum number of shares of Pernix common stock issuable in the transaction based on a price range of $6.00-$9.00 per share.
News For PTX;SOMX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 20, 2015
08:31 EDTPTXPernix Therapeutics sees Q4 net revenue in excess of $52M, consensus $46.26M
08:31 EDTPTXPernix Therapeutics sees FY14 net revenue in excess of $120M, consensus $114.16M
Subscribe for More Information
January 15, 2015
15:45 EDTPTXPernix Therapeutics announces sNDA for Treximet accepted by FDA
Pernix Therapeutics Holdings announced that its supplemental New Drug Application, sNDA, for Treximet has been accepted by the FDA. Approval is expected in 2Q 2015, based on the anticipated Prescription Drug User Fee Act, PDUFA, action date. The company’s sNDA, submitted on November 14 seeks approval for Treximet for use in adolescent patients, age 12–17, for the acute treatment of migraine with or without aura. Included in the filing are safety and efficacy data sets from three trials conducted to evaluate the pharmacokinetic, efficacy, and long-term safety of Treximet for the acute treatment of adolescent migraine. To date, there is no sumatriptan or combination prescription medication for the treatment of acute migraine attacks with or without aura approved for use in this population. Presently, Treximet is approved in the U.S. for the acute treatment of migraine with or without aura in adults.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use